RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Surface specifically modified NK-92 cells with CD56 antibody conjugated superparamagnetic Fe(3)O(4) nanoparticles for magnetic targeting immunotherapy of solid tumors.
Surface specifically modified NK-92 cells with CD56 antibody conjugated superparamagnetic Fe(3)O(4) nanoparticles for magnetic targeting immunotherapy of solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管肿瘤免疫疗法的开发已取得显著进展,但实体瘤的治疗仍面临许多挑战。自然杀伤(NK)细胞对肿瘤具有广谱细胞毒性,但其有限的迁移和浸润能力限制了它们在实体瘤治疗中的应用。在此,我们将一种简便高效的磁靶向策略与基于NK细胞的疗法相结合,开发出一种用于治疗实体瘤的新型免疫治疗方法。将抗CD56抗体与Fe 3 O 4纳米颗粒偶联,可特异性结合NK-92细胞,赋予其磁场驱动的靶向能力。这些NK-Fe 3 O 4生物杂化纳米颗粒能够在外部磁场引导下促进体内向肿瘤部位定向迁移,并有效抑制肿瘤生长。这些功能化NK细胞代表了一种实体瘤治疗的新方法,并可能在未来为癌症干预提供一种有前景的模式。
Although there has been significant progress in the development of tumor immunotherapies, many challenges still exist for the treatment of solid tumors. Natural killer (NK) cells possess broad-spectrum cytotoxicity against tumors, but their limited migration and infiltration abilities restrict their application in solid tumor therapies.
Here, we combined a facile and efficient magnetic-targeting strategy with NK cell-based therapy to develop a novel immunotherapy approach for treating solid tumors. Anti-CD56 antibodies were conjugated with Fe 3 O 4 nanoparticles, which could specifically bind with NK-92 cells endowing them with a magnetic field driven targeting ability.
These NK-Fe 3 O 4 biohybrid nanoparticles were able to facilitate directional migration to the tumor site in vivo under external magnetic field guidance and efficiently inhibit tumor growth. These functionalized NK cells represent a novel approach for solid tumor therapy and may provide a promising modality for cancer interventions in the future.
MEMBER ACCOUNT
登录成功会直接打开下一页。